What is Sofie Biosciences?
Sofie Biosciences operates at the intersection of biotechnology and medical diagnostics, focusing on the development of integrated radiochemistry and imaging systems. The company is dedicated to democratizing access to theranostics—a field that combines diagnostic imaging with targeted therapy. By maintaining a robust radiopharmacy network and acting as a contract manufacturing organization, Sofie Biosciences provides the essential infrastructure required to supply novel agents for disease management. Their market position is defined by a commitment to removing barriers to entry for advanced biological research and clinical application, effectively bridging the gap between complex laboratory science and practical patient care.
How much funding has Sofie Biosciences raised?
Sofie Biosciences has raised a total of $55.6M across 6 funding rounds:
Series A
$5M
Grant
$1.5M
Private Equity
$3.7M
Series B
$16M
Debt
$2M
Series C
$27.4M
Series A (2013): $5M with participation from MRM Capital, Cycad Group, and Tata Industries
Grant (2014): $1.5M led by MRM Capital and Cycad Group
Private Equity (2016): $3.7M supported by Artiman Managment, LLC
Series B (2018): $16M featuring Mayor Richard Riordan
Debt (2020): $2M backed by PPP
Series C (2020): $27.4M with participation from Jubilant Pharma Limited
Key Investors in Sofie Biosciences
MRM Capital
MRM Capital Holdings specializes in providing creative private equity solutions and strategic advisory services to maximize investment opportunities for middle-market companies.
Cycad Group
Cycad Group is a venture capital firm focused on investing in technology across various sectors, including healthcare and biopharmaceuticals, to address unmet market needs.
Tata Industries
Tata Industries is part of a prominent global conglomerate with a diverse portfolio, providing strategic support to companies engaged in innovation and industrial development.
What's next for Sofie Biosciences?
With a history of successful capital raises, including Series A through Series C rounds, Sofie Biosciences is well-positioned for its next phase of enterprise-level growth. The company is expected to leverage its recent financing to scale its radiopharmacy infrastructure and expand its portfolio of diagnostic agents. As the firm matures, strategic focus will likely shift toward increasing the adoption of its proprietary imaging systems across global clinical markets. By maintaining its focus on operational efficiency and technological accessibility, Sofie Biosciences is poised to remain a leader in the evolving landscape of precision medicine and molecular diagnostics.
See full Sofie Biosciences company page
